Last update:


Arch Hellen Med, 32(3), May-June 2015, 295-301


The efficacy and safety of novel anti-obesity therapies

A.K. Papazafiropoulou,1 N. Papanas,2 A. Melidonis1
1First Department of Internal Medicine and Diabetes Center, "Tzaneio" General Hospital of Pireus, Pireus,
2Diabetes Clinic, Second Department of Internal Medicine, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece

Obesity is a chronic disease with a high prevalence in both developed and developing countries. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, continue to be the cornerstone of weight-reduction programs. Novel anti-obesity drug therapies are currently gaining in importance. These include lorcaserin (a selective serotonin agonist), phentermine/topiramate combination, naltrexone/bupropion combination (acting on the hypothalamus), and liraglutide, an established anti-diabetic agent which suppresses the appetite. This is a brief review of the evidence on the role of these anti-obesity drugs in the management of obesity.

Key words: Bupropion, Liraglutide, Lorcaserin, Naltrexone, Obesity, Phentermine, Topiramate.

© Archives of Hellenic Medicine